Company intelligence / Profile preview

Grelan Pharmaceutical

Ownership: Private
Development stage: Phase 3

Overview

Grelan Pharmaceutical was a Japanese company that developed and commercialized small molecule therapeutics, including fenofibrate for lipid disorders (PPARα agonist). They also had a pipeline candidate, GP-1447, for diabetic cataract. The company was acquired and merged into ASKA Pharmaceutical in 2005, ceasing to exist as an independent entity.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

Tavocept

Phase 3

Indications: Breast cancer, Non-small cell lung cancer, Ovarian cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Grelan Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grelan Pharmaceutical.

Explore the full profile